← Back to Search

Calcium Channel Blocker

A first, then B for High Blood Pressure

Phase 4
Waitlist Available
Led By Dempsey Hughes, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up endpoints will be measured before the first dose of either amlodipine or chlorthalidone and at the end of each six-week double-blinded treatment period
Awards & highlights

Study Summary

This trial is testing two different medications to see which is more effective in lowering blood pressure for liver transplant patients.

Eligible Conditions
  • High Blood Pressure
  • Liver Transplant
  • Kidney Dysfunction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~endpoints will be measured before the first dose of either amlodipine or chlorthalidone and at the end of each six-week double-blinded treatment period
This trial's timeline: 3 weeks for screening, Varies for treatment, and endpoints will be measured before the first dose of either amlodipine or chlorthalidone and at the end of each six-week double-blinded treatment period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in central aortic pressure at 6 weeks of therapy compared to baseline values
Secondary outcome measures
Change in Blood pressure
Change in Renal function
Number of patients with improvement in diastolic function (E/e' ratio)
+1 more

Trial Design

2Treatment groups
Active Control
Group I: A first, then BActive Control2 Interventions
6 weeks of drug A followed by a 2-week washout period completed with 6 weeks of drug B
Group II: B first, then AActive Control2 Interventions
6 weeks of drug B followed by a 2-week washout period completed with 6 weeks of drug A

Find a Location

Who is running the clinical trial?

American Society for TransplantationUNKNOWN
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,814 Previous Clinical Trials
47,290,875 Total Patients Enrolled
Northwestern UniversityLead Sponsor
1,576 Previous Clinical Trials
911,922 Total Patients Enrolled

Media Library

Amlodipine Besylate (Calcium Channel Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT05275907 — Phase 4
High Blood Pressure Research Study Groups: A first, then B, B first, then A
High Blood Pressure Clinical Trial 2023: Amlodipine Besylate Highlights & Side Effects. Trial Name: NCT05275907 — Phase 4
Amlodipine Besylate (Calcium Channel Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05275907 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please provide an estimate of the total number of individuals involved in this clinical experiment?

"Affirmative, the information on clinicaltrials.gov attests to this study's current recruitment campaign which began on July 12th, 2022 and was recently updated a day later. 15 participants are expected from one location."

Answered by AI

How would you rate the security of individuals when using A prior to B?

"With the Phase 4 trial indicating that both A and B have been approved, our team at Power gave them a safety rating of 3 out of three."

Answered by AI

Is enrollment in this trial still open to volunteers?

"Per the information published on clinicaltrials.gov, this trial is currently recruiting participants since its July 12th 2022 posting date and latest edit of July 13th 2022."

Answered by AI
Recent research and studies
~0 spots leftby Mar 2025